Inactive Instrument

Sterling Green Group PLC London S.E.

GB00B1N0T068

Pharmaceuticals

End-of-day quote London S.E. Other stock markets
- ^GBX	-

2023	Amryt Pharma plc(NasdaqGS:AMYT) dropped from S&P Global BMI Index	CI
2023	Amryt Pharma plc(NasdaqGS:AMYT) dropped from NASDAQ Composite Index	CI

Fastnet Oil & Gas PLC : Change of Joint Broker

December 05, 2013 at 02:45 am EST

MarketScreener.com By

5 December 2013

Fastnet Oil & Gas plc

("Fastnet" or the "Company")

Change of Joint Broker

Fastnet (AIM: FAST, ESM: FOI) the listed E&P company focused on near term exploration acreage in Morocco and the Celtic Sea, announces the appointment of GMP Securities Europe LLP as the Company's Joint Broker, with immediate effect.

Shore Capital continues as the Company's Nominated Adviser and Joint Broker and Davy continues as ESM Adviser and Joint Broker.

For further information, please contact:

Fastnet Oil & Gas plc Cathal Friel, Chairman Paul Griffiths, Managing Director	+353 (1) 644 0007

Shore Capital (Nominated Adviser & Joint Broker) Nomad Bidhi Bhoma Edward Mansfield Corporate Broking Jerry Keen	+44 (0)20 7408 4090
GMP Securities Europe LLP (Joint Broker) Rob Collins	+44 (0)20 7467 2800
Davy (ESM Adviser & Joint Broker) John Frain Anthony Farrell	+353 (1) 679 6363
FTI Consulting Edward Westropp Natalia Erikssen James Styles	+44 (0)207 831 3113

This information is provided by RNS

The company news service from the London Stock Exchange

ENDMSCEAKALEEPDFFF

distributed by

Latest news about Sterling Green Group PLC

Amryt Pharma plc(NasdaqGS:AMYT) dropped from S&P Global BMI Index	23-04-13	CI
Amryt Pharma plc(NasdaqGS:AMYT) dropped from NASDAQ Composite Index	23-04-12	CI
Chiesi Farmaceutici S.p.A. completed the acquisition of Amryt Pharma plc from Athyrium Capital Management, LP, Highbridge Capital Management, LLC, Joe Wiley, Rory Nealon, Ray Stafford and others.	23-04-11	CI
Amryt Pharma's Shareholders Approve Acquisition by Chiesi Farmaceutici	23-03-22	MT
Amryt Pharma plc’s Equity Buyback announced on March 9, 2022, has expired.	23-03-07	CI
HC Wainwright Downgrades Amryt Pharma to Neutral From Buy, Cuts Price Target to $14.50 From $18	23-01-18	MT
Maxim Group Downgrades Amryt Pharma to Hold From Buy	23-01-10	MT
Cantor Fitzgerald Downgrades Amryt Pharma to Neutral From Overweight, Adjusts Price Target to $14.75 From $25	23-01-10	MT
Canaccord Genuity Downgrades Amryt Pharma to Hold From Buy, Adjusts Price Target to $17 From $19	23-01-10	MT
Sector Update: Health Care Stocks Largely Struggle Monday	23-01-09	MT
Top Midday Gainers	23-01-09	MT
Sector Update: Health Care Stocks Struggling to Begin New Week	23-01-09	MT
Sector Update: Health Care	23-01-09	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	23-01-09	MT
Rate Hike Clues, China Border Reopening Fuel Gains for US Equity Futures	23-01-09	MT
Top Premarket Gainers	23-01-09	MT
Amryt Pharma to be Acquired by Chiesi Farmaceutici	23-01-09	MT
Italy's Chiesi Farmaceutici to Buy Rare Disease-focused Amryt Pharma for $1.5 Billion	23-01-09	MT
Chiesi Farmaceutici S.p.A. entered into a definitive agreement to acquire Amryt Pharma plc from Athyrium Capital Management, LP, Highbridge Capital Management, LLC, Joe Wiley, Rory Nealon, Ray Stafford and others for $1.1 billion.	23-01-07	CI
Amryt Pharma Says Phase 3 Trial of Cholesterol Disorder Treatment Met Primary Endpoint; Shares Gain Pre-Bell	23-01-05	MT
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH	23-01-05	CI
Amryt Says European Medicines Agency Committee Adopts Positive Opinion on Orphan Designation for Mycapssa	22-12-19	MT
Amryt Pharma Receives Approval for Mycapssa in Europe	22-12-05	MT
Amryt Announces European Commission Approves Mycapssa® for the Treatment of Acromegaly	22-12-05	CI
Amryt Pharma Says It Received New US Patent for Mycapssa	22-11-30	MT

Chart Sterling Green Group PLC

Duration

Period

More charts

Company Profile

Amryt Pharma plc is a commercial-stage biopharmaceutical company. It is focused on acquiring, developing, and commercializing novel treatments for rare diseases. Its commercial business comprises three orphan disease products, such as metreleptin (Myalept/ Myalepta); lomitapide (Juxtapid/ Lojuxta), and oral octreotide (Mycapssa). Myalept is approved in the United States as an adjunct to diet as replacement therapy to treat leptin deficiency in patients with congenital or acquired generalised lipodystrophy (GL). Juxtapid is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, homozygous familial hypercholesterolaemia (HoFH). Mycapssa is a combination of octreotide acetate and excipients, collectively called Transient Permeability Enhancer (TPE). Its development candidate, Oleogel-S10 (Filsuvez) is a treatment for the cutaneous manifestations of junctional and dystrophic (JEB and DEB) epidermolysis bullosa.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-1.58%	89.22B
SAMSUNG BIOLOGICS CO.,LTD.	+2.24%	40.49B
BIOGEN INC.	-12.97%	32.79B
UCB	+61.72%	26.23B
BIOMARIN PHARMACEUTICAL INC.	-20.71%	14.52B
INCYTE CORPORATION	-7.31%	13.09B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.64%	11.5B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.60%	11.6B
SWEDISH ORPHAN BIOVITRUM AB	+4.27%	8.82B

Biopharmaceuticals

Sterling Green Group PLC London S.E.

Equities

GB00B1N0T068

Pharmaceuticals

Fastnet Oil & Gas PLC : Change of Joint Broker

Latest news about Sterling Green Group PLC

Chart Sterling Green Group PLC

Company Profile

Sector Biopharmaceuticals